The Rapidly Evolving Role of PSMA In Prostate Cancer Diagnostics And Therapeutics

The Rapidly Evolving Role of PSMA In Prostate Cancer Diagnostics And Therapeutics

Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein which functions as a zinc metalloenzyme and is found on prostatic epithelium. In normal...

FAM64A is an androgen receptor-regulated feedback tumor promoter in prostate cancer

FAM64A is an androgen receptor-regulated feedback tumor promoter in prostate cancer

cell death & disease Cell Death & Disease volume 12, Article number: 668 (2021) Cite this article 1 Altmetric Predictive markers Abstract Endocrine therapy for prostate cancer...

Risk of esophageal and gastric adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer

Risk of esophageal and gastric adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer

Risk of esophageal and gastric adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer Oesophageal cancer Abstract The aim of this study was to explore...

Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer

Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer

Question  Are external beam radiotherapy, with or without brachytherapy boost, or radical prostatectomy associated with differences in prostate cancer–specific mortality or...

Updates in Immune Checkpoint Inhibitors for Prostate Cancer

Updates in Immune Checkpoint Inhibitors for Prostate Cancer

SHARE Updates in Immune Checkpoint Inhibitors for Prostate Cancer In spite of the rapid progress and many exciting advances in the treatment of metastatic castration-resistant...

Research Suggests How Tumors Evolve to Become Aggressive Form of Prostate Cancer

Research Suggests How Tumors Evolve to Become Aggressive Form of Prostate Cancer

The genetic changes that underlie an especially lethal type of prostate cancer have been revealed in a new study by investigators at Weill Cornell Medicine. Learning more about...

Active Surveillance for Intermediate-Risk Prostate Cancer Linked With Lower Survival - Renal and Urology News

Active Surveillance for Intermediate-Risk Prostate Cancer Linked With Lower Survival - Renal and Urology News

Active surveillance (AS) should be cautiously offered to men with intermediate-risk prostate cancer, investigators suggest. Thenappan Chandrasekar, MD, and colleagues from...

Prostate Cancer Risk Lower in NSAID Users - Renal and Urology News

Prostate Cancer Risk Lower in NSAID Users - Renal and Urology News

Use of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with a decreased risk of prostate cancer (PCa), according to researchers. The protective effect is more...

Persistent Cancer Screening Gaps Revealed in New CDC Report - Renal and Urology News

Persistent Cancer Screening Gaps Revealed in New CDC Report - Renal and Urology News

Share by Email According to a report from the Centers for Disease Control and Prevention, from 2000 to 2015, screening for breast, cervical, and prostate cancers decreased...

New research paves way for improved prostate cancer treatments

New research paves way for improved prostate cancer treatments

Anti-androgen therapy can fuel spread of bone tumours in advanced prostate cancer Anti-androgen therapy is commonly used to treat patients with advanced prostate cancer at...

Not All High-Risk Prostate Cancers Are the Same - Renal and Urology News

Not All High-Risk Prostate Cancers Are the Same - Renal and Urology News

Researchers have identified distinct subgroups of men with high-risk prostate cancer (PCa) who experience different outcomes following treatment with a combination of high-dose...

MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer

MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer

MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer Scientific Reports volume 11, Article number: 13305 (2021) Cite this article 228 Accesses Targeted...